
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A
For years, market watchers have speculated about some biopharma giant or other buying out BioMarin Pharmaceutical (NASDAQ: BMRN), which is why the rare disease drug developer has appeared in every GEN A-List of Top 10 Takeover Targets, from 2013 through …